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Abstract
Background: Oncolytic adenoviruses are promising agents for the multimodal treatment of
cancer. However, tumor-selectivity is crucial for their applicability in patients. Recent studies by
several groups demonstrated that oncolytic adenoviruses with tumor-/tissue-specific expression of
the E1 and E4 genes, which are pivotal for adenoviral replication, have a specificity profile that is
superior to viruses that solely target the expression of E1 or E4 genes. Presently the E1 and E4
regions are modified in a time consuming sequential fashion.
Results: Based on the widely used adenoviral cloning system AdEasy we generated a novel transfer
vector that allows efficient and rapid generation of conditionally replication-competent adenovirus
type 5 based vectors with the viral E1 and E4 genes under the transcriptional control of
heterologous promoters. For insertion of the promoters of interest our transfer vector has two
unique multiple cloning sites. Additionally, our shuttle plasmid allows encoding of a transgene within
the E1A transcription unit. The modifications, including E1 mutations, are introduced into the
adenoviral genome by a single homologous recombination step in Escherichia coli. Subsequently
infectious viruses are rescued from plasmids. As a proof-of-concept we generated two
conditionally replication-competent adenoviruses Ad.Ki•COX and Ad.COX•Ki with the
promoters of the Ki-67 protein and the cyclooxygenase-2 (COX-2) driving E1 and E4 and vice
versa.
Conclusion:  We demonstrated with our cloning system efficient generation of double
heterologous promoter controlled oncolytic adenoviral vectors by a single homologous
recombination step in bacteria. The generated viruses showed preferential replication in tumor
cells and in a subcutaneous HT-29 colon cancer xenograft model the viruses demonstrated
significant oncolytic activity comparable with dl327.
Background
Human adenoviruses normally infect a wide variety of
both dividing and nondividing cells. They replicate in and
lyse their host cells to release newly generated progeny
virus. Although these properties are ideal for killing
human cancer cells, virus replication must be restricted to
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malignant cells preferably without toxicity to normal sur-
rounding cells. The clinical relevance is emphasized by the
lack of an established effective therapy for serious, dissem-
inated adenovirus infection [1,2]. Oncolytic adenoviruses
can be armed by therapeutic transgenes to augment their
anticancer capacity [3-5]. Furthermore they can enhance
synergistically chemotherapy and/or radiation in a multi-
modal anti-neoplastic approach [3,6,7]. To improve the
safety and the therapeutic index of replication-competent
adenoviral vectors, many unique strategies have been
developed in an attempt to achieve tumor selectivity [8].
In one approach, viral genes that are essential for viral rep-
lication are placed under the control of promoters that are
preferentially active in tumor cells compared to the sur-
rounding normal tissues.
After adenoviral infection, E1A is the first viral gene
expressed, and its product trans-activates the other pro-
moters of early genes allowing expression of late genes,
upon which viral replication depends [9]. Thus, the most
commonly used strategy to construct conditionally repli-
cation-competent adenoviruses is to place only the aden-
oviral E1A region under the control of tissue/tumor-
specific promoters [10-13]. Since already small amounts
of E1A gene products are sufficient to initiate adenoviral
replication resulting in the accumulation of E1A gene
products and thus driving viral replication [14], leaky rep-
lication is frequently observed with this strategy. Control-
ling both E1A and E1B genes with a tissue/tumor-specific
promoter improves the tissue/tumor-specific replication
of the virus [15].
Like the E1 gene products, the adenoviral E4 gene region
is expressed early after infection and is an essential com-
ponent of the viral life cycle. The adenoviral E1 and E4
gene products function in concert to create a cellular envi-
ronment permissive for efficient expression and process-
ing of viral gene products and ultimately a productive
virus infection [16].
Several groups reported that controlling simultaneously
the expression of E1A and E4 genes will provide a tighter
control over virus replication [17-22] and at the same time
decreases the risk of generation of wild-type revertants.
Because of the difficulty in finding two active and tightly
regulated promoters for a certain tumor type that main-
tain their specificity in the adenoviral genome [23] several
groups placed the E1 and E4 genes under the control of
the same promoter [19-21]. Others used two different het-
erologous promoters to control E1 and E4 expression
[17,18,22].
In a previous study [22] we demonstrated that transcrip-
tional targeting of solitary E1A resulted in ~50%
improved vector targeting when compared to an unre-
stricted replication-competent adenovirus. Furthermore,
we showed that transcriptional targeting of adenoviral
E1A and E4 with different promoters enhances vector tar-
geting when compared to vectors using the same pro-
moter.
In these studies, E1 and E4 double heterologous promoter
controlled adenoviruses were generated by a lengthy
sequential multistep cloning procedure to replace the viral
E1 and E4 promoter [19,20,22]. Another approach in E.
coli involves a multistep modification of the transfer vec-
tor which had to be done for each inserted heterologous
promoter individually [18]. Aside from recombination
systems in E. coli [24,25] the adenoviral genome can also
be modified efficiently in yeast [26,27]. Fuerer et al. used
a multistep recombination system in yeast to introduce
multiple heterologous promoters/enhancers in the aden-
oviral genome [17].
Since among current methods there is no simple proce-
dure to generate replication-competent adenoviral vectors
with double heterologous promoters driving the viral E1
and E4 region, we developed based on the widely used
adenoviral cloning system AdEasy [24,25] a transfer vec-
tor with two unique multiple cloning allowing the con-
venient insertion of heterologous promoters to
transcriptionally target the expression of adenoviral E1
and E4 genes. In addition, the new transfer vector can
accommodate a transgene, which is followed by an inter-
nal ribosomal entry site (IRES) upstream of the viral E1A
transcription unit. This design has been used by us previ-
ously to generate replication competent adenoviral vec-
tors encoding the herpes simplex virus thymidine kinase
(HSV-TK), green fluorescent protein (GFP) or luciferase
[2,4,28,29]. In the meantime we generated also double
heterologous promoter controlled conditionally replica-
tion-competent adenoviral vectors encompassing a 24 bp
deletion in the E1A conserved region 2 domain (E1Δ24),
corresponding to amino acids L122TCHEAGF129, that is
required for retinoblastoma protein (pRB) binding and
release of E2F from pRb, which is associated with cell pro-
liferation [30].
To evaluate the utility of our technology, we replaced the
adenoviral E1 and E4 promoter with the COX-2 or Ki-67
promoter, respectively. Cyclooxygenase-2 (COX-2),
which is primarily responsible for prostaglandins pro-
duced in inflammatory sites and is virtually undetectable
in most tissues under physiological conditions, is upregu-
lated in breast, bladder, lung, pancreas, as well as colon
cancer [31]. The Ki-67 protein is exclusively expressed in
proliferating cells and is therefore an important diagnostic
tool for the detection of malignancies [32]. Previously we
demonstrated that the COX-2 and Ki-67 promoter main-
tains their specificity in the adenoviral context [23]. InBMC Biotechnology 2006, 6:36 http://www.biomedcentral.com/1472-6750/6/36
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contrast to the often used cell cycle dependent E2F1 pro-
moter, the activity of the Ki-67 promoter is not influenced
by the adenoviral E1A gene products, which release free
E2F by interacting with pRB [33].
In this proof-of-concept study we demonstrated efficient
and straightforward generation of oncolytic adenoviruses
with E1 and E4 driven by heterologous promoters. We
evaluated the adenoviruses Ad.Ki•COX and Ad.COX￿Ki
in vitro and in vivo. We will make the shuttle plasmids
available to the scientific community for noncommercial
purposes.
Results
We constructed two shuttle plasmids with wild-type ade-
novirus E1 and the mutant E1Δ24 [33] both allowing in a
single homologous recombination step in E. coli  to
replace the viral E1 and E4 promoter with heterologous
promoters (strategy outlined in Fig. 1). In this proof-of-
concept study we evaluated the transfer vector pShuttle#4-
1 with wild-type E1 by generating two replication-compe-
tent adenoviruses Ad.Ki￿COX and Ad.COX￿Ki based on
the pAdEasy-1 adenoviral backbone.
Analysis of promoter activity
Before inserting the promoters for the COX-2 and Ki-67
gene into our transfer vector pShuttle#4-1, we confirmed
the specificity of these promoters. For this we conducted
transient dual luciferase reporter gene assays in the color-
ectal cancer cell line HT-29 and the pancreatic cancer cell
line Panc1. Primary normal human keratinocytes (HKC)
served as a control. As shown in Fig. 2, when compared to
the CMV-IE promoter, the median activity of the COX-2
promoter in these cells (subconfluent) was 19.5%, 39.1%,
and 0.5%, respectively. In cells arrested in G0/G1 or
infected with Ad5, the activity of the COX-2 promoter did
not change significantly (P = NS, Student's t test). When
compared to the CMV-IE promoter, the median activity of
the Ki-67 promoter in subconfluent cells was 18.7%,
27.2%, and 11.9%, respectively. Infection of the cells with
Ad5 had no significant effects on the activity of the Ki-67
promoter (P = NS, Student's t test). However, the activity
of the Ki-67 promoter was reduced to background levels
in G0/G1 arrested cells (P < 0.001, Student's t test). Flow
cytometric analysis of cell cycle distribution revealed that
~96% of the cells were in G0/G1 (data not shown).
Efficient generation of double heterologous promoter 
controlled adenoviruses
To place the adenoviral E1 and E4 genes under the tran-
scriptional control of the COX-2 and Ki-67 promoter we
inserted these promoters in the appropriate multiple clon-
ing site of our transfer vector generating pShuttle#4
COX￿Ki and pShuttle#4 Ki￿COX. To reduce promoter
interference, we placed upstream of the promoters a syn-
thetic polyA site [23].
After linearization of the transfer vectors, they were
recombined with the adenoviral backbone plasmid
pAdEasy-1 via their homologous DNA in E. coli. The struc-
ture of the recombined plasmid pAd.Ki￿COX with cleav-
age sites for the restriction endonucleases used for analysis
is shown in Fig. 3A. The plasmid pAd.Cox￿Ki is identical
with the exception of the promoters for E1 and E4. As
shown in Fig. 3B, restriction analysis of kanamycin resist-
ant clones with Hind III demonstrated that only one out
of 20 analyzed clones resulted from non-recombined
transfer vector. Restriction of the adenoviral plasmids
pAd.Ki￿COX and pAd.COX￿Ki with Pac I revealed that in
4 out of 10 and in 5 out of 9 recombinants homologous
recombination occurred between the corresponding arms
of shuttle and adenoviral backbone plasmid. In the other
cases, recombination occurred between the ori sequences
shared by the transfer vector and the adenoviral backbone
plasmid pAdEasy-1 and the corresponding right arms. In
these clones the native viral E4 promoter has not been
replaced with the heterologous promoter of interest.
As shown in Fig. 3C we further analyzed the recombinants
pAd.Ki￿COX and pAd.COX￿Ki by Spe I and Swa I double
digestion to release the heterologous promoter driving the
viral E4 region. Electrophoretic analysis resulted in a frag-
ment in the length of the COX-2 promoter (597 bp) and
Ki-67 promoter (814 bp) with upstream polyA, as well as
in a 31.1 kb and a 5.9 kb fragment. The heterologous pro-
moter driving the viral E1 region is incorporated in the
~3.5 kb Cla I fragment. Because neither pAdEasy-1 nor the
shuttle plasmid contains the native viral E1 promoter,
recombinants encoding E1 under the transcriptional con-
trol of the native viral E1 promoters are not possible in E.
coli.
Since both the COX-2 and the Ki-67 promoter were active
in subconfluent 293 cells, we used these cells to rescue
recombinant replication-competent adenoviruses, as
described previously [25]. As shown in Fig. 3D we verified
the genomic integrity of the rescued infectious adenovi-
ruses Ad.Ki￿ COX and Ad.COX￿Ki by PCR amplification
of the Ki-67 and COX-2 promoter sequences with
upstream polyA. The size of the PCR amplified fragments
were 792 bp and 582 bp, respectively, as expected. Ad5
served as negative control.
Adenoviral cytopathic effect assay
We determined the Ad5 transduction efficiency of all cell
lines used in this study. For this cell monolayers were
incubated for 24 hours with Ad.GFP at an MOI of 0.5
PFU/cell (determined on 293 cells by TCID50). In HT-29,
Panc1, PAC and 293 cells the median fraction of GFP pos-BMC Biotechnology 2006, 6:36 http://www.biomedcentral.com/1472-6750/6/36
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itive was ~45%. Under the same conditions, the median
transduction efficiency of PPC and primary human kerat-
inocytes (HKC) was 21.6% and 9.3%, respectively.
Since all vectors are based on Ad5 and thus penton base
and fiber which determine the infection efficiency on the
viral side are identical, we used the transduction efficiency
with Ad.GFP for individual infection conditions for each
cell line to compensate for differences in adenoviral trans-
duction efficiency. With the Ad.GFP vector we verified the
applicability of our predicted compensation (data not
shown).
Strategy outline Figure 1
Strategy outline. To generate E1 and E4 heterologous promoter controlled replication-competent adenoviral vectors, the 
promoters of interest are inserted into the appropriate multiple cloning sites (MCS) of the transfer vector pShuttle#4-1 (or 
pShuttle#4-1Δ24). E. coli BJ5183 cells are transformed with the adenoviral backbone plasmid pAdEasy-1 or pTG3602 and the 
linearized transfer vector. Recombinants resistant to kanamycin are analyzed by restriction enzyme analysis to determine 
whether homologous recombination occurred at the corresponding "left arm" and "right arm". Subsequently infectious recom-
binant adenovirus is rescued from 293 cells.
pShuttle#4-1
n
a
K
X
I
L A
E
1
5' ITR
3' ITR
A R

MCS1
A L
R A
Amp
pAdEasy-1 or
pTG3602
n a K
3' ITR
 Amp
R A
A L
Ori
BJ5183
E. coli Linearize
Pac I
Transgene IRES
Ad.P •P 12
+/- E3
E4 E1

E 4
a 2 IV
Transgene
5' ITR
Promoter 1
Promoter 2
Ori
IRES
Ori
pAd.P •P 12
3' ITR 5' ITR
Promoter 1 Promoter 2
Pme I
i
r
O
M
C
S
2
3' ITRBMC Biotechnology 2006, 6:36 http://www.biomedcentral.com/1472-6750/6/36
Page 5 of 12
(page number not for citation purposes)
To determine the adenoviral cytopathic effect, monolay-
ers of HT-29, Panc1 and HKC were infected with serial
dilutions of dl327, Ad.Ki￿COX and Ad.COX￿Ki. As shown
in Fig. 4A, Ad.Ki￿COX and Ad.COX￿Ki demonstrated lysis
of HT-29 and Panc1 cell monolayers. The lytic effect of
Ad.COX￿Ki in both cell lines tested was slightly greater
than that of Ad.Ki￿COX. Furthermore, the lytic effect of
the recombinant adenoviruses in HT-29 and Panc1 was
similar to that of dl327. In contrast, in primary human
keratinocytes, the cytopathic effect of the adenoviruses
Ad.Ki￿COX and Ad.COX￿Ki was greatly reduced when
compared to dl327.
Since permanent cell lines might have changed their char-
acteristics over time, we verified our cytopathic effect assay
also in primary pancreatic carcinoma cells (PPC). As a
control for normal cells we used primary adenoid cells
(PAC) in addition to HKC (Fig. 4B). Infection of PPC cells
with dl327, Ad.Ki￿COX, or Ad.COX￿Ki resulted in com-
plete lysis of the cell monolayers. Furthermore, infection
of the non-neoplastic HKC or PAC cells with dl327 caused
complete cytopathic effect. In contrast, infection of the
monolayers with the viruses Ad.Ki￿COX or Ad.COX￿Ki
did not cause any significant cell lysis, with the exception
of Ad.COX￿Ki in HKC cells where a slight cytopathic effect
was visible.
In vivo evaluation of the oncolytic adenoviruses
Furthermore we evaluated in an HT-29 subcutaneous
colon carcinoma model in nude mice the oncolytic effi-
cacy of the double heterologous promoter controlled vec-
tors (Ad.Ki￿COX, and Ad.COX￿Ki) and the adenoviral E3-
deletion mutant dl327. As shown in Fig. 5, on day 28, the
median tumor volume of untreated animals was 1408.6
mm3. The median tumor volume of animals treated with
dl327, Ad.Ki￿COX, or Ad.COX￿Ki was 241.7 mm3, 383.8
mm3, and 290.7 mm3, respectively.
One-Way Analysis of Variance (ANOVA) with Tukey's
HSD post hoc test revealed that the tumor volumes of all
treatment groups receiving adenovirus were significantly
smaller when compared to untreated animals (P  <
0.0001). Furthermore there was no statistical significant
difference in the treatment efficacy of Ad.Ki￿COX,
Ad.COX￿Ki and dl327 (P = NS).
Discussion
In the context of conditionally replication-competent ade-
noviral vectors, several groups reported that dual tran-
Luciferase reporter assays Figure 2
Luciferase reporter assays. The specificity of the COX-2 and Ki-67 promoter was confirmed using a dual luciferase 
reporter assay, allowing the analysis of test promoters via firefly luciferase activity and normalization of transfection efficiency 
via Renilla reniformis luciferase driven by the constitutive CMV-IE promoter in a single-well. Promoter activity was measured in 
subconfluent or G0/G1-arrested cells. To examine whether adenoviral gene products influence the promoter activity cells 
were infected with Ad5 after transfection with the reporter plasmids. The activity of the COX-2 and Ki-67 promoter was nor-
malized to that of the CMV-IE promoter. Data are presented as mean ± SD from four independent experiments.
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scriptional targeting of viral E1A and E4 genes allows a
significantly higher level of tumor specificity than solely
targeting E1A or E4 genes [17-22]. In these studies, E1 and
E4 double heterologous promoter controlled adenovi-
ruses were generated by a timely multistep cloning proce-
dure to replace the viral E1A and E4 promoter by tumor-/
Cloning of oncolytic adenoviruses Ad.Ki•COX and Ad.COX•Ki Figure 3
Cloning of oncolytic adenoviruses Ad.Ki•COX and Ad.COX•Ki. Panel A: The structure of the recombined adenoviral 
plasmid pAd.Ki•COX is shown. Restriction endonucleases used for analysis are mapped. For clarity, a map of pAd.COX•Ki, 
which is with the exception of the swapped promoters identical to pAd.Ki•COX, has been omitted. Panel B: BJ5183 cells pre-
transformed with pAdEasy-1 were transformed with pShuttle#4 Ki•COX and pShuttle#4 COX•Ki. The integrity of the 
pAdEasy-1 plasmid in the pre-transformed E. coli was confirmed by Hind III digestion (data not shown). For each construct ten 
small scale DNA plasmid preparations of kanamycin resistant clones were digested with Hind III and Pac I and analyzed by elec-
trophoresis through a 0.8% agarose gel and ethidium bromide staining. Panel C: High quality DNA was prepared by CsCl 
banding of potential valid recombinants and digested with Pac I, Spe I/Swa I, Cla I, and Hind III. The heterologous promoter driv-
ing the viral E4 region was flanked by Spe I and Swa I and the promoter controlling E1 by Cla I. The adenoviral backbone plas-
mid pAdEasy-1 served as a control. Diagnostic fragments obtained with each enzyme are marked with an asterisk (*). Panel D: 
Standard PCR was used to confirm on the rescued infectious recombinant adenoviruses Ad.Ki•COX and Ad.COX•Ki the pres-
ence of the Ki-67 and COX-2 promoter with the upstream polyA sequences in each virus. Ad5 served as negative control. The 
1 kb DNA ladder from Invitrogen/Gibco was used as DNA size marker (M).
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tissue-specific promoters in a sequential fashion. In this
proof-of-concept study we demonstrated efficient and
straightforward generation of conditionally replication-
competent adenoviruses with E1 and E4 genes driven by
heterologous promoters.
Previous studies demonstrated that not all promoters are
suitable for the transcriptional targeting of adenoviral E4
gene products [20,34] and that heterologous promoters
might lose their specificity in the adenoviral context
[35,36]. Therefore it is likely that several adenoviral vec-
tors with different heterologous promoters have to be gen-
erated and evaluated for their tumor specificity. Thus our
system will be valuable for the generation of conditionally
replication-competent adenoviral vectors with E1 and E4
driven by tumor-/tissue-specific promoters.
Dependent on the used adenoviral backbone plasmid, i.e.
pAdEasy-1 [25] or pTG3602 [24], our system allows gen-
eration of E3-deleted or wild-type E3 vectors.
Deletion of the adenoviral E3 region allows insertion of
larger promoters and/or transgenes but reduces also the
intrinsic oncolytic capacity of these vectors [37,38].
Analogous to our oncolytic adenovirus vectors encoding
HSV-TK, GFP or luciferase [2,4,28,29], our system allows
the incorporation of a transgene into the E1A transcrip-
tion unit. This design allows high transgene expression.
Since the level of E1A expression has only a slight effect on
virus replication [14], in these vectors the replication was
not significantly affected. In addition, mutations of the E1
region, e.g. ΔE1B-55K [39] or E1Δ24/dl922-947 [33], can
be easily incorporated into this system as long as this
region is not present in the used adenoviral backbone
plasmid (e.g. Ad.Easy-1).
As a proof-of-concept we generated with our novel trans-
fer vector two adenoviruses Ad.Ki￿COX and Ad.COX￿Ki
with the promoters of the Ki-67 protein and the cyclooxy-
genase-2 (COX-2) driving E1 and E4 and vice versa. We
choose the COX-2 and Ki-67 promoter since we did know
from previous studies that these promoters maintain their
specificity in the adenoviral genome and in the presence
of adenoviral gene products [23]. Furthermore, since for
most tumors it is difficult to specify a truly tumor specific
promoter we combined the tumor-/tissue-specific pro-
Anti-neoplastic efficacy of adenoviruses Figure 5
Anti-neoplastic efficacy of adenoviruses. HT-29 
xenografts were grown subcutaneously to volumes of ~200 
mm3. Groups of mice (n = 8) were treated with indicated 
adenoviruses by intratumoral injection of 5 × 109 virus parti-
cles in 100 μl PBS on day 0 and day 2. Tumors were meas-
ured at indicated time points and calculated volumes (mean ± 
SD) are presented as growth curves.
Untreated
dl327
Ad.KiyCOX
Ad.COXyKi
0 7 14 21 28
0
500
1000
1500
2000
Time [days]
T
u
m
o
r
v
o
l
u
m
e
[
m
m
³
]
Adenoviral cytopathic effect assay Figure 4
Adenoviral cytopathic effect assay. Panel A: Monolay-
ers of HT-29, Panc1, and primary human keratinocytes 
(HKC) were infected with serial dilutions of dl327, and aden-
oviral vectors carrying the adenoviral E1A region and E4 
under the transcriptional control of the COX-2 or Ki-67 
promoter, respectively. The indicated MOI (PFU/cell) was 
determined for each cell line individually. Panel B: monolay-
ers of primary pancreatic carcinoma cells (PPC), HKC, and 
primary adenoid cells (PAC) were left untreated or infected 
at an MOI of 5 PFU/cell (determined for each cell line individ-
ually) with dl327, Ad.Ki•COX or Ad.COX•Ki, respectively. 
Five days later, the cells were washed and stained. One rep-
resentative experiment out of three is shown.
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moter COX-2 with a proliferation-associated Ki-67 pro-
moter to target viral replication and lysis to the
transcriptional intersection of these two promoters.
The COX-2 promoter was active in the tested colon and
pancreatic cancer cell lines, but not in human keratinoc-
ytes which we used as a control for normal cells. In con-
trast to the E2F promoter often used in oncolytic
adenoviral vectors [11,19], the Ki-67 promoter is not acti-
vated in plasmid based reporter gene assays when over
infected with wild-type Ad5 [23]. To our knowledge this is
the first report using this promoter in oncolytic adenoviral
vectors.
In ~50% of the recombinants generated with our novel
shuttle vector, the viral E4 promoter was replaced with the
heterologous E4 promoter. In recombinants generated by
homologous recombination of the shuttle plasmid and
pAdEasy-1 ori sequences the viral E4 promoter will not be
substituted with the heterologous promoter. The effi-
ciency was influenced by the promoter sequence and
length. Up to now we were able to replace the viral E4 pro-
moter efficiently with heterologous promoters of up to
1.5 kb in length. Using the adenoviral backbone plasmid
pAdEasy-1 or pTG3602, heterologous sequences with a
total length of up to 4.4 kb or 2.6 kb, respectively, can be
inserted [40].
In vitro, the constructed double heterologous promoter
controlled replication-competent adenoviral vectors
Ad.Ki￿COX and Ad.COX￿Ki demonstrated efficient lysis
of the tested colon and pancreas cancer cell lines, but poor
lysis in primary human keratinocytes (HKC). In contrast,
the cytopathic effect caused by dl327 infection was similar
in all cell lines tested. Since permanent cell lines have
been often in continuous culture for several years and thus
are likely to have genetic aberrations, we established
short-term cultures of primary pancreatic cancer cells.
Both recombinant adenoviruses and dl327 demonstrated
efficient cell lysis of these cells. In contrast, Ad.Ki￿COX
and Ad.COX￿Ki showed greatly reduced cell lysis in short-
term cultures of primary adenoid cells and keratinocytes
when compared to dl327. Because we compared the cyto-
pathic effect of the Ad.Ki￿COX and Ad.COX￿Ki vectors to
dl327, we put special emphasis on the titer determination
of dl327, since an underestimation of dl327 titer would
have put the specificity of the vectors Ad.Ki￿COX and
Ad.COX￿Ki into doubt.
Furthermore, since in all adenoviruses the E3-11.6K pro-
tein (ADP) was deleted, which is required for efficient
cells lysis and release of adenoviral progeny from infected
cells [37] and thus resulting in reduced viral replication
kinetics when compared to wild-type Ad5 [28], the differ-
ences in cytopathic effect seen are clearly due to the pro-
moter substitution.
We also evaluated in a subcutaneous HT-29 colon
xenograft model in nude mice the oncolytic activity of the
viruses Ad.Ki￿COX, Ad.COX￿Ki and dl327. The key find-
ings were: First, intratumoral injections of replication-
competent adenoviruses resulted in a significant anti-
tumor response when compared to untreated animals,
confirming that replication-competent adenoviruses have
a direct oncolytic activity [39,41]. Second, the anti-neo-
plastic efficacy of the unrestricted replication-competent
dl327 virus was similar to that of the vectors Ad.Ki￿COX
and Ad.COX￿Ki. Third, although at any given time only a
fraction of tumor cells are in S phase there was no signifi-
cant difference in the anti-neoplastic efficacy of
Ad.Ki￿COX and Ad.COX￿Ki.
Conclusion
We demonstrated in our proof-of-concept study that our
novel transfer vector allows efficient and straight forward
generation of double heterologous promoter controlled
adenoviruses in a single homologous recombination step
in bacteria. Dependent on the used adenoviral backbone
plasmid, i.e. pAdEasy-1 or pTG3602, our system allows
generation of E3-deleted or wild-type E3 vectors. The res-
cued infectious adenoviruses demonstrated preferential
lysis of tumor cells, thus confirming previous reports on
restriction of adenoviral replication by transcriptional tar-
geting of the viral E1A and E4 region. The use of tumor-
specific promoters to control the expression of viral genes
pivotal for replication is a promising method for the con-
struction of therapeutic viruses.
Methods
Cells and cell culture
The cell lines HT-29 (HTB-38), Panc1 (CRL-1469), and
293 (CRL 1573) were obtained from the American Type
Culture Collection (Manassas, VA) and propagated in D-
10 medium, consisting of high glucose DMEM medium
supplemented with 10% heat-inactivated fetal bovine
serum, 50 μg/ml gentamicin, and 2 mM glutamine (Invit-
rogen/Gibco, Paisley UK). Primary human keratinocytes
(HKC) were kindly provided by K. Reimers (Klinik für
Plastische, Hand- und Wiederherstellungschirurgie,
MHH, Hannover, Germany) and propagated in Promo-
Cell Keratinocyte Growth Medium 2 (Promocell GmbH,
Heidelberg, Germany). As an additional control for nor-
mal cells, we established short term cultures of adenoid
cells, designated PAC, from children who underwent ton-
sillectomy for medical reasons. Since permanent tumor
cell lines might have changed their characteristics during
the course of continuous culture, we established also
short-term cultures of pancreatic cancer cells, designated
PPC, from patients treated surgically for histologicallyBMC Biotechnology 2006, 6:36 http://www.biomedcentral.com/1472-6750/6/36
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confirmed pancreatic cancer. Ethical clearance was
obtained from the local Ethics Committee (Reg. No.
2487). Cells were obtained from tissue by mechanical dis-
ruption and enzymatic digestion with DNAse I (80 mg/
ml), hyaluronidase (2000 U/ml) and collagenase (40 mg/
ml) (Sigma-Aldrich, St. Louis, MO). Cells were grown in
DMEM/F12 (1:1) medium supplemented with 10% heat-
inactivated fetal bovine serum, 50 μg/ml gentamicin, and
2 mM glutamine. All cell lines were maintained at 37°C
in a humidified atmosphere of 95% air and 5% CO2.
Plasmids, DNA transfections, and luciferase reporter 
assays
The COX-2 (-327/+59) promoter fragment [42] was PCR
amplified with the primers 5'-GAGCTCGAAGAAGAAAA-
GACATCTGGCG-3' and 5'-CTCGAGGCGCTGCTGAG-
GAGTTCCTG-3' and subsequently inserted into the Sac I/
Xho I sites (underlined in the primer sequence) of the luci-
ferase reporter vector pGL3-Basic (Promega, Madison,
WI). The Ki-67 (-600/+7) promoter fragment [43] was
PCR amplified using the primers 5'-CTCGAGGATAG-
CAGGACGGGTTATCT-3' and 5'-AAGCTTTTCCACTT-
GTCGAACCACCG-3' and cloned into the Xho I/Hind III
sites (underlined in the primer sequence) of pGL3-Basic.
Promoter studies were carried out using a dual luciferase
reporter assay (Promega), allowing the analysis of test
promoters via firefly luciferase activity and normalization
of transfection efficiency via Renilla reniformis luciferase
driven by the constitutive CMV-IE promoter in a single-
well. For promoter analysis in subconfluent cell monolay-
ers, cells were seeded one day prior to transfection at a
density of 1 × 104 cells per well into 24-well tissue culture
plates. Cell monolayers were co-transfected with 9.9 μg
firefly reporter vector DNA and 0.1 μg DNA of the Renilla
luciferase expression plasmid pRL-CMV (Promega) using
the calcium phosphate method [44].
To determine whether adenovirus early gene products
influence the activity of the tested promoters, cells were
infected with dl327 at a multiplicity of infection (MOI) of
5 PFU/cell 36 hours after transfection with reporter gene
plasmids. Forty-eight hours after transfection, cell lysates
were analyzed using a microplate luminometer (Berthold
ORION-96, Bad Wildbad, Germany), as described previ-
ously [23]. Studies were carried out in four independent
experiments using two preparations of plasmid DNA from
the E. coli strains DH5α and Stbl2 (Invitrogen/Gibco).
Arrest and analysis of cell cycle
Forty-two hours after transfection cells were arrested in
G0/G1 by UV irradiation (25 J/m2) using a Stratalinker
1800 UV Crosslinker (Stratagene, La Jolla, CA), as
described previously [45]. The dose of UV radiation used
was optimized for best cell cycle arrest with minimal
induction of apoptosis. Six hours later, luciferase reporter
gene assays and flow cytometric cell cycle analysis were
carried out as described previously [23].
Adenoviral cloning system
Our cloning system consists of two plasmid vectors: The
pAdEasy-1 adenoviral backbone plasmid, provided by
Bert Vogelstein (Johns Hopkins Kimmel Cancer Center,
Baltimore, MD) [25] contains the entire adenovirus type
5 (Ad5) genome except nucleotides 1 – 3,533 (encom-
passing the E1 region) and nucleotides 28,130 – 30,820
(encoding E3).
To increase the probability of generating recombinant
plasmids containing the recombinant adenoviral genome,
we used BJ5183 cells carrying intact pAdEasy-1 plasmid
[46]. Since the large backbone is susceptible to damage
during the transformation procedure, the used batch of
pAdEasy-1 transformed BJ5183 cells was tested by restric-
tion enzyme analysis and the ability to rescue infectious
adenovirus from recombinant plasmids.
The new component is our transfer vector pShuttle#4-1,
which encodes, in contrast to pShuttle [25], the entire Ad5
E1 region (right arm, Ad5 nucleotides 499 – 5767; for
comparison pShuttle Ad5 nt 3,534–5,790). The viral E1A
promoter has been replaced with a multiple cloning site
containing a BamH I, Srf I, Not I, Xho I, and Sal I restriction
site to allow insertion of a heterologous promoter or pro-
moter and transgene which is then transcriptionally
linked with the adenoviral E1 gene through an internal
ribosome entry site (IRES) sequence. Furthermore, the
viral E4 promoter has been replaced with a second MCS
with the restriction sites Spe I, Nsp V, Swa I and Nhe I. The
left arm encompasses Ad5 nucleotides 33639 – 35617
(for comparison pShuttle 34,931–35,935). Left and right
arm allow homologous recombination with the adenovi-
ral plasmid (pAdEasy-1). The adenoviral 3' ITR, multiple
cloning sites and appropriate restriction sites for inserting
PCR cloned adenoviral arms were created by a 229 bp syn-
thetic linker with the sequence GGTACCGGATC-
CGCCCGGGCGCGGCCGCCTCGAGGTCGACAACTTAA
GGATATCGTATACGTTTAAACGAATTCATCGATTCTA-
GAGCTAGCATTTAAATTTCGAAACTAGTCTACGTCAC-
CCGCCCCGTTCCCACGCCCCGCGCCACGTCACAAAC
TCCACCCCCTCATTATCATATTGGCTTCAATC-
CAAAATAAGGTATATTATTGATGATGTTAATTAACAT-
ATG inserted into the Kpn I and Nde I restriction sites of
pShuttle, flanking 5' the adenoviral encapsidation signal
(ψ) and 3' pBR322 origin of replication and kanamycin
resistance gene.
To facilitate the insertion of promoters in our transfer vec-
tor pShuttle#4-1 from the reporter plasmid pGL3-Basic
(Promega), we generated the plasmid pBS-linker, which
contains between the Sac I – Kpn I site of pBS SK+ (Strata-BMC Biotechnology 2006, 6:36 http://www.biomedcentral.com/1472-6750/6/36
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gene, La Jolla, CA) a multiple cloning site with the endo-
nuclease restriction sites Spe I, Nsp V, Not I, EcoR V, Hind
III, Sal I, and Swa I. The COX-2 and Ki-67 promoters were
inserted with the upstream synthetic polyA from pGL3-
Basic as Not I – Hind III fragments into the plasmid pBS-
linker and then into pShuttle#4-1 as Not I – Sal I frag-
ments for driving E1A and as Spe I – Swa I fragments into
the second MCS to control transcription of E4.
As outlined in Fig. 1, after insertion of both promoters
and facultative a transgene into pShuttle#4-1, the transfer
vector needs to be linearized with Pme  I (alternatively
EcoR I or Bst1107 I). Subsequently pAdEasy-1 pre-trans-
formed [46] electrocompetent E. coli  BJ5183 cells are
transformed with the linearized transfer vector. Alterna-
tively pTG3602 can be used as adenoviral backbone. Sec-
ond, recombinants were selected with kanamycin and
screened by Hind III restriction endonuclease digestion.
Since the native viral E4 promoter will only be replaced
with the heterologous promoter if the homologous
recombination occurred between left and right arms of
pAdEasy-1 and transfer vector, recombinants with com-
plex Hind III restriction pattern were digested with Pac I.
If the homologous recombination occurred between the
left arms a ~3 kb and ~35 kb fragment will result. How-
ever, if the recombination occurred through the plasmid
ori sequences shared between the transfer and pAdEasy-1
vector a 4.5 kb and ~35 kb fragment will occur. The result-
ing adenoviral recombinants are single heterologous pro-
moter controlled replication-competent vectors with a
native viral E4 promoter. In the last step, recombinant
adenoviral constructs are digested with Pac I to liberate
ITRs and transfected into a production cell line, i.e. 293
cells. If the heterologous E4 promoter does not work in
this cell line, the viral E4 function needs to be trans-com-
plemented.
Adenoviruses
The adenoviruses Ad.COX￿Ki and Ad.Ki￿COX with the
COX-2 and Ki-67 promoter driving E1 and E4 and vice
versa were generated as proof-of-concept with our novel
transfer vector. The genomic integrity of Ad.COX￿Ki and
Ad.Ki￿COX was verified by PCR for the presence of the Ki-
67 and COX-2 promoter with upstream polyA. Adenoviral
DNA was isolated using the Genomed JETQUICK Tissue
Spin Kit (GENOMED, Löhne, Germany) according to the
manufacturer's instructions. For amplification of polyA-
Ki-67 promoter the primer pair GGCCG-
CAATAAAATATCTTT and CAAGCTTTTCCACTTGTCGA
was used. The polyA-COX-2 promoter was amplified with
the primer pair GCGGCCGCAATAAAATATCT and GTC-
GACAAGCTTACTTAGAT.
Adenoviral infection susceptibility of the cell lines was
determined with Ad.GFP, a previously described vector
encoding green fluorescence protein (GFP) driven by the
CMV-IE promoter [47]. The E3-deleted Ad5 mutant dl327
[48] was used as unrestricted replication-competent aden-
ovirus control, and the reference strain VR-5 (ATCC, Man-
assas, VA) was used as wild-type Ad5. Since in
subconfluent 293 cells both the COX-2 and Ki-67 pro-
moter [49] were active, all adenoviruses were amplified in
293 cells and purified by two rounds of CsCl density cen-
trifugation and subsequent dialysis [50]. Concentration
and bioactivity of the adenoviruses were determined by
measuring absorbency at 260 nm and 50% tissue culture
infective doses (TCID50) using 293 cells [51].
Adenoviral infectivity assay
Cells were seeded (1 × 106 cells per well) into 6-well plates
and 12 hours later incubated for 4 hours with Ad.GFP at a
multiplicity of infection (MOI) of 5, 1, and 0.5 PFU per
cell (determined on 293 cells). Twenty-four hours later,
GFP expression was analyzed by flow cytometry (FACS-
Calibur flow cytometer, Becton Dickinson Immunocy-
tometry Systems, Mansfield, MA)
Cytotoxicity assay
To determine viral cytopathic effect, 2 × 105 and 1 × 106
cells were seeded into 24-well and 6-well plates. Cell
monolayers were infected under the same conditions with
the adenoviruses at an MOI of 0.1 to 50 and 5 PFU/cell in
1 ml or 5 ml D-10 growth medium, respectively. The dose
of infection was adapted based on the transduction effi-
ciency with an Ad5-based adenoviral vector encoding
GFP. The infectious titer of Ad.GFP was determined by
TCID50 on 293 cells. Four hours later, cell monolayers
were washed and incubated with fresh growth medium.
Within a day when complete lysis of monolayers infected
with dl327 occurred (~5 days post infection) remaining
cells were washed, fixed with 2% paraformaldehyde, sub-
sequently stained with 1% crystal violet and photo-
graphed.
Animal study
This study was approved by the local Animal Care and Use
Committee. The anti-neoplastic efficacy of the adenoviral
vectors was determined in a subcutaneous HT-29 tumor
xenograft model in nude mice. For this, 5 to 7 weeks-old
BALB/c  nu/nu  mice (Janvier, Le Genest-St-Isle, France)
were injected with 1 × 107 HT-29 cells in 100 μl subcuta-
neously into the hind flanks. At least once a week, mini-
mum and maximum perpendicular tumor axes were
measured using vernier calipers, and tumor volume was
calculated using the simplified formula of a rotational
ellipse (l × w2 × 0.5).
When the tumors reached a volume of ~200 mm3, ani-
mals were randomly assigned to treatment groups and
received two intratumoral injections of 5 × 109 virus par-BMC Biotechnology 2006, 6:36 http://www.biomedcentral.com/1472-6750/6/36
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ticles diluted in a volume of 100 μl phosphate-buffered
saline (PBS) on day 0 and day 2. The untreated group
received PBS.
Statistical analysis
The software SPSS 12 (SPSS Inc., Chicago, IL) was used for
statistical analysis with the indicated test.
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